Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer Metastatic|Breast Cancer Female|Breast Cancer Recurrent
Interventions: DRUG: Faceptor|DRUG: Herceptin|DRUG: Docetaxel
Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company
Collaborators: Vietstar Biomedical Research|MedProve Inc